Search results for "PSORIASIS"

showing 10 items of 193 documents

Blocking TNF in vitro with infliximab determines the inhibition of expansion and interferon gamma production of Vγ9/Vδ2 T lymphocytes from patients w…

2011

Side effects of TNF neutralisation - mostly infectious complications - were recognized, the most important being pulmonary tuberculosis infections. gamma/ d T cells contribute to protective immune response against mycobacterium tuberculosis.The aim of the present study was to assess the expansion capacity of Vgamma9/Vdelta2 T cells from (tuberculin purified protein derivative (PPD) positive and PPD negative) patients with active rheumatoid arthritis (RA), and to examine the in vitro effect of infliximab on this lymphocyte subset.28 PPD negative RA patients were studied and compared with 14 PPD positive RA patients, 45 PPD-negative and 110 PPD-positive healthy volunteers. Cell separation, ex…

Malelcsh:Internal medicineTuberculosisT-Lymphocyteslcsh:MedicineArthritisTuberculinArthritis RheumatoidInterferon-gammaRheumatologyPsoriasismedicineHumanslcsh:RC31-1245Tuberculosis PulmonaryCells CulturedAgedAnkylosing spondylitisInterferon-gamma productionTumor Necrosis Factor-alphabusiness.industrylcsh:RAntibodies MonoclonalMiddle Agedmedicine.diseaseInfliximabInfliximabAntirheumatic AgentsRheumatoid arthritisImmunologyFemaleTumor necrosis factor alphabusinessmedicine.drug
researchProduct

Skin Sodium Accumulates in Psoriasis and Reflects Disease Severity

2020

Sodium can accumulate in the skin at concentrations exceeding serum levels. A high sodium environment can lead to pathogenic T helper 17 cell expansion. Psoriasis is a chronic inflammatory skin disease in which IL-17. producing T helper 17 cells play a crucial role. In an observational study, we measured skin sodium content in patients with psoriasis and in age-matched healthy controls by Sodium-23 magnetic resonance imaging. Patients with PASI > 5 showed significantly higher sodium and water content in the skin but not in other tissues than those with lower PASI or healthy controls. Skin sodium concentrations measured by Sodium-23 spectroscopy or by atomic absorption spectrometry in ashed-…

Malemedicine.medical_specialtySodiumchemistry.chemical_elementInflammationImiquimodDermatologySodium ChlorideLymphocyte ActivationSeverity of Illness IndexBiochemistryArticleMiceInternal medicinePsoriasismedicineExtracellularAnimalsHumansPsoriasisT helper 17 cellMolecular BiologyCells CulturedSkinintegumentary systembusiness.industrySpectrophotometry AtomicSpectrum AnalysisInterleukin-17SodiumCell DifferentiationCell Biologymedicine.diseasePathophysiologyMice Inbred C57BLEndocrinologychemistryCardiovascular and Metabolic DiseasesTh17 Cellsmedicine.symptombusinessIntracellularmedicine.drugJournal of Investigative Dermatology
researchProduct

Psoriasis and its impact on the clinical outcome of patients with pulmonary embolism

2021

Abstract Background Venous thromboembolism (VTE) is common and associated with high morbidity and mortality. Although chronic inflammation was not categorized as a traditional risk factor for VTE, chronic inflammation might increase the risk to develop VTE events. While studies confirmed an increased cardiovascular morbidity and mortality in psoriatic patients, data regarding the influence of psoriasis on patients' cardiovascular profile and on prognosis of patients with pulmonary embolism (PE) are sparse. Purpose We aimed to investigate the impact of psoriasis on prognosis of PE patients. Methods Hospitalized PE patients were stratified for psoriasis and the impact of psoriasis on outcome …

Malemedicine.medical_specialtyYounger agebusiness.industryVenous Thromboembolismmedicine.diseasePulmonary embolismVenous thrombosisIncreased riskRisk FactorsInternal medicinePsoriasismedicineHumansPsoriasisFemaleHospital MortalityPulmonary EmbolismCardiology and Cardiovascular MedicinebusinessVenous thromboembolismAgedEuropean Heart Journal
researchProduct

Successful outcome of psoriasis in a laryngeal cancer patient treated with ixekizumab, a possible beneficial treatment for both pathologies.

2021

Malemedicine.medical_specialtybusiness.industryInterleukin-17CancerAntineoplastic AgentsDermatologyGeneral MedicineMiddle Agedmedicine.diseaseAntibodies Monoclonal HumanizedDermatologyOutcome (game theory)IxekizumabPsoriasisCarcinoma Squamous CellMedicineHumansPsoriasisbusinessLaryngeal NeoplasmsDermatology online journal
researchProduct

Efficacy of switching between tumor necrosis factor-alfa inhibitors in psoriasis: results from the Italian Psocare registry

2014

Background: Some studies have shown that switching patients from one tumor necrosis factor (TNF)-alfa inhibitor to another may be beneficial when they have an inadequate response or an adverse event. Objective: We sought to assess the variables predicting the efficacy of the second TNF-alfa inhibitor in patients discontinuing the first TNF-alfa inhibitor. Methods: Data from all 5423 consecutive patients starting TNF-alfa inhibitor therapy for psoriasis between September 2005 and September 2010 who were included in the Italian Psocare registry were analyzed. Results: In 105 patients who switched to a second TNF-alfa inhibitor who had complete follow-up data, 75% improvement in the Psoriasis …

Maleprimary inefficacy75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitors; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Immunoglobulin G; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young AdultSWITHCESefficacyTNFpsoriasis; psoriasis arthritis; pharmachological treatmentPASI 75Severity of Illness IndexReceptors Tumor Necrosis FactorEtanerceptCohort StudiesMonoclonalReceptorsSettore MED/35 - Malattie Cutanee E VenereeRegistriesHumanizedtumor necrosis factor-alfa inhibitors.switchingHazard ratioAntibodies MonoclonalMiddle AgedTreatment OutcomeItalyPredictive value of tests75% improvement in the Psoriasis Area Severity Index scoreFemaleDrugPsoriasis Area Severity IndexbiologicTNF-alphaAdultmedicine.medical_specialtytumor necrosis factorDermatology75% improvement in the Psoriasis Area Severity Index score; PASI; PASI 75; Psoriasis Area Severity Index; TNF; biologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor; tumor necrosis factor-alfa inhibitorsAntibodies Monoclonal Humanizedsecondary loss of efficacyRisk AssessmentAntibodiestumor necrosis factor-alfa inhibitorsDrug Administration ScheduleDose-Response RelationshipYoung AdultSettore MED/35Predictive Value of TestsInternal medicinePsoriasisSeverity of illnessmedicineConfidence IntervalsHumansPsoriasisbiologicsAdverse effectPsoriasis; TNF-alphaProportional Hazards ModelsRetrospective Studiespsoriasibiologics; efficacy; primary inefficacy; psoriasis; secondary loss of efficacy; switching; tumor necrosis factor-alfa inhibitors; Adalimumab; Adult; Analysis of Variance; Antibodies Monoclonal; Antibodies Monoclonal Humanized; Cohort Studies; Confidence Intervals; Dose-Response Relationship Drug; Drug Administration Schedule; Etanercept; Female; Follow-Up Studies; Humans; Immunoglobulin G; Infliximab; Italy; Male; Middle Aged; Multivariate Analysis; Predictive Value of Tests; Proportional Hazards Models; Psoriasis; Receptors Tumor Necrosis Factor; Registries; Retrospective Studies; Risk Assessment; Severity of Illness Index; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult; 2708Analysis of Variancepharmachological treatmentDose-Response Relationship DrugProportional hazards modelbusiness.industrytumor necrosis factor-alfa inhibitorTumor Necrosis Factor-alphaPASIAdalimumabRetrospective cohort studypsoriasis arthritismedicine.diseaseConfidence intervalInfliximabSurgeryImmunoglobulin GMultivariate AnalysisANTI-TNFAbusiness2708Follow-Up Studies
researchProduct

Willingness to pay for a cure of low-risk melanoma patients in Germany

2018

Malignant melanoma is potentially life-threatening but in most cases curable if detected early. Willingness to pay (WTP) is a preference-based construct that reflects burden of disease by assessment of the monetary value for a hypothetical cure from disease. Since WTP (directly as total amount of money) has not been assessed so far in patients with low risk melanoma, it was interesting to gain insights in this patient population and then, in a second step, compare it directly with the WTP of their treating dermato-oncologists. WTP was assessed in 125 patients with low-risk melanoma and additionally in 105 treating physicians, asking for the one-time and continuous payments they would be wil…

MelanomasMaleSkin NeoplasmsMedical DoctorsEconomicsHealth Care ProvidersCancer TreatmentMedizinSocial Scienceslcsh:MedicineDisease030207 dermatology & venereal diseases0302 clinical medicineSociologyCost of IllnessMedizinische FakultätGermanySurveys and QuestionnairesMedicine and Health SciencesOdds RatioPublic and Occupational HealthMedical Personnellcsh:ScienceMelanomaMultidisciplinaryMelanomaPatient PreferenceMiddle AgedProfessionsOncology030220 oncology & carcinogenesisIncomeFemaleResearch ArticleAdult-Education03 medical and health sciencesHealth EconomicsBreast cancerWillingness to payDiagnostic MedicinePhysiciansPsoriasisCancer Detection and DiagnosismedicineHumansddc:610Educational AttainmentAgedNeoplasm StagingHealth economicsbusiness.industrylcsh:RCancers and Neoplasmsmedicine.diseaseHealth CareRosaceaPeople and PlacesCutaneous melanomaPopulation Groupingslcsh:QbusinessFinanceDemography
researchProduct

Leishmania infection in psoriasis

2019

Microbiology (medical)PsoriasiLeishmaniasibiologybusiness.industryTNFLeishmaniasisLeishmaniabiology.organism_classificationmedicine.diseaseBiologicalImmunosuppressiveInfectious DiseasesPsoriasisImmunologymedicineHumansPsoriasisTumor necrosis factor alphabusinessLeishmaniasis
researchProduct

Effectiveness of cyclosporine A in patients with moderate to severe plaque psoriasis in a real-life clinical setting in Italy: the TRANSITION study

2020

Background: Cyclosporine A (CsA) is one of the systemic therapeutic options for moderate-to-severe psoriasis, based on its efficacy and rapidity of action. The current study investigated the response to CsA in patients with moderate-to-severe plaque psoriasis. Materials and Methods: TRANSITION was an observational, cross-sectional, multicentre study which evaluated the proportion of partial- and suboptimal-responders among patients with moderate-to-severe plaque psoriasis treated with continuous CsA for >= 12 weeks. Patients demonstrating a Psoriasis Area and Severity Index (PASI) response of >= 90, >= 75 and <90, >= 50 and <75 and <50 were defined as responders, subopt…

Moderate to severeMalemedicine.medical_specialtysystemic therapy.macromolecular substancesDermatologySystemic therapySeverity of Illness Indexsystemic therapy030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicinePsoriasisMedicineHumansPsoriasisIn patientPASI; cyclosporine A; moderate to severe plaque psoriasis; systemic therapy030203 arthritis & rheumatologyPlaque psoriasisbusiness.industryPASIMiddle Agedmedicine.diseasemoderate to severe plaque psoriasiDermatologycyclosporine A; moderate to severe plaque psoriasis; PASI; systemic therapyCross-Sectional StudiesTreatment OutcomeCyclosporineQuality of LifeFemalebusinesscyclosporine Amoderate to severe plaque psoriasis
researchProduct

A Rare Presentation of Mycosis Fungoides Mimicking Psoriasis Vulgaris

2009

Mycosis fungoides (MF) is an uncommon primary cutaneous lymphoma with a wide spectrum of clinicopathological manifestations. Diagnosis can be difficult in its early stages given the considerable overlap with more common benign dermatoses. We report an unusual case of MF in a 52-year-old male presenting with psoriasiform plaques on the palms and the soles who rapidly developed additional lesions on the scalp, limps and trunk. Punch biopsy of the face was obtained for routine histology and immunohistochemical stains. Chest X-ray, total body computed tomography scanning and excisional biopsy of the inguinal lymph node were performed. Review of the face biopsy revealed a diffuse dermal infiltra…

Mycosis fungoidesMycosis fungoidesPathologymedicine.medical_specialtyAtypical LymphocyteMycosis fungoides Cutaneous lymphoma Psoriasismedicine.diagnostic_testbusiness.industryHistologyDermatologylcsh:RL1-803medicine.diseaseDermatologyCutaneous lymphomamedicine.anatomical_structureImmunophenotypingCutaneous lymphomaPsoriasisScalpBiopsymedicinelcsh:DermatologyCase Reports in DematologyPsoriasisbusinessCase Reports in Dermatology
researchProduct

Sekund�re Gicht bei Hautkrankheiten

1967

Nach Ausfuhrungen uber Atiopathogenese und neuere Einteilung der Gicht in zwei Varietaten wird kasuistisch uber die Entwicklung einer sekundaren Gicht ohne Hautbeteiligung bei einer Mycosis fungoides sowie bei einer Psoriasis vulgaris berichtet. Anhand des Schrifttums uber Basiserkrankungen sekundarer Gicht, insbesondere dermatologischer Herkunft, wird erstmalig die Mycosis fungoides als vermutlich uberzufalliges Grundleiden fur die Entstehung einer sekundaren Gicht diskutiert.

Mycosis fungoidesmedicine.medical_specialtySecondary goutbusiness.industryDermatologyGeneral Medicinemedicine.diseaseDermatologyGoutchemistry.chemical_compoundchemistryPsoriasismedicineUric acidbusinessArchiv f�r Klinische und Experimentelle Dermatologie
researchProduct